Back to results
US 11,884,735 B2Granted
Agonistic anti-IL-2R antibodies and methods of use
AssigneeTeneoBio, Inc.
InventorsNathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
Life of this patent
Estimating the term…
Abstract
Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
Claims25
A heavy chain-only antibody comprising:
- a first heavy chain variable region that binds to IL2RB, comprising:
- a CDR1 sequence comprising the formula:
- G G S I S S S X1 W (SEQ ID NO:
- 26)
- wherein X1 is D or N;
- and
- a CDR2 sequence comprising the formula:
- I X2 H S G S T (SEQ ID NO:
- 27)
- wherein X2 is D or S;
- and
- a CDR3 sequence comprising the formula:
- X3 R G X4 W E L X5 D A F D I (SEQ ID NO:
- 28)
- wherein X3 is G or A;
- X4 is S or Q;
- and
- X5 is S or T;
- and
- a second heavy chain variable region that binds to IL2RG, comprising:
- a CDR1 sequence comprising the formula:
- G F X1 X2 X3 X4 Y Y (SEQ ID NO:
- 32)
- wherein X1 is T or I;
- X2 is F or V;
- X3 is S, N, or G;
- and
- X4 is D or N;
- and
- a CDR2 sequence comprising the formula:
- I S X5 S G X6 X7 I (SEQ ID NO:
- 33)
- wherein X5 is S or N;
- X6 is D, S, G, or N;
- and
- X7 is T or I;
- and
- a CDR3 sequence comprising the sequence ARGDAVSITGDY (SEQ ID NO:
- 20).
36 more elements
Dependencies are inferred from the claim text.